Fibrogen Inc CS (FGEN)

$10.83 +0.12 (1.12%)
Market Cap 43.31M
Revenue (ttm) 29.62M
Net Income (ttm) -47.58M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -160.63%
Debt to Equity Ratio -0.36
Volume 14,300
Avg Vol 36,724
Day's Range N/A - N/A
Shares Out 4.04M
Stochastic %K 36%
Beta 0.76
Analysts Sell
Price Target $43.00

Company Profile

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 10 #6009, San Francisco, United States
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 25 at 7:48 AM
$FGEN Procyanidin displayed a synergistic effect with roxadustat on renal anemia in mice https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1678846/abstract
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:05 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $FGEN Current Share Price: $10.88 Contracts: $FGEN January 15, 2027 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
mjtwins16
mjtwins16 Oct. 23 at 6:27 PM
$FGEN https://pubmed.ncbi.nlm.nih.gov/41079599/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=0x09UMLZ1ZyMLjbskVJ3kd6MHfZTZyaCGRc7NzobTEJ&fc=None&ff=20251023004005&v=2.18.0.post22+67771e2
0 · Reply
mjtwins16
mjtwins16 Oct. 23 at 6:26 PM
$FGEN
0 · Reply
AceInTheHole18
AceInTheHole18 Oct. 23 at 6:13 PM
$BCTX $FGEN game on!
0 · Reply
MaxMiamiFl
MaxMiamiFl Oct. 23 at 5:05 PM
$FGEN
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 3:04 PM
$FGEN in an hour and a half of trading, the volume of shares is 279 pieces :). Everyone is waiting for something.
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 9:17 AM
$FGEN https://www.kingnet.com.tw/news/single?newId=49293
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 9:14 AM
$FGEN https://pubmed.ncbi.nlm.nih.gov/41079599/
0 · Reply
Value10
Value10 Oct. 22 at 2:36 AM
$FGEN SEC Earnings Date for FGEN has not been announced, however it is usually the 1st week in November. I would expect some guidance at that time… especially since there now only 2 drugs, no office space, a P.O. Box, little debt… and $150 million in Cash. They may not give it away entirely, but we should get some idea of where we are going.
0 · Reply
Latest News on FGEN
FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

Sep 24, 2025, 7:00 AM EDT - 4 weeks ago

FibroGen Initiates Phase 2 Monotherapy Trial of FG-3246, a First-in-Class CD46 Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 4:02 PM EDT - 2 months ago

FibroGen to Present at the H.C. Wainwright 27th Annual Global Investment Conference

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

Aug 18, 2025, 7:00 AM EDT - 2 months ago

FibroGen Announces Approval of Sale of FibroGen China to AstraZeneca by the China State Administration for Market Regulation

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:55 PM EDT - 2 months ago

FibroGen, Inc. (FGEN) Q2 2025 Earnings Call Transcript

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 11, 2025, 4:02 PM EDT - 2 months ago

FibroGen Reports Second Quarter 2025 Financial Results and Provides Business Update

FibroGen to Report Second Quarter 2025 Financial Results

Aug 4, 2025, 4:02 PM EDT - 2 months ago

FibroGen to Report Second Quarter 2025 Financial Results

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Jun 13, 2025, 8:22 AM EDT - 4 months ago

Adobe, FibroGen And Other Big Stocks Moving Lower In Friday's Pre-Market Session

ADBE

FibroGen Announces 1-for-25 Reverse Stock Split

Jun 12, 2025, 4:02 PM EDT - 4 months ago

FibroGen Announces 1-for-25 Reverse Stock Split

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

Jun 9, 2025, 4:02 PM EDT - 4 months ago

FibroGen Appoints Michael Kauffman, M.D., Ph.D. to its Board of Directors

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:31 PM EDT - 5 months ago

FibroGen, Inc. (FGEN) Q1 2025 Earnings Call Transcript

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:02 PM EDT - 5 months ago

FibroGen Reports First Quarter 2025 Financial Results and Provides Business Update

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

May 8, 2025, 4:24 AM EDT - 6 months ago

Duchenne Muscular Dystrophy (DMD) Pipeline Insight Report 2025, Featuring Analysis of Vamorolone (Santhera), Givinostat (Italfarmaco), and Pamrevlumab (Fibrogen)

FibroGen to Report First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 6 months ago

FibroGen to Report First Quarter 2025 Financial Results

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

Apr 2, 2025, 4:05 PM EDT - 7 months ago

FibroGen to Participate in the 24th Annual Needham Virtual Healthcare Conference

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 8:18 PM EDT - 7 months ago

FibroGen, Inc. (FGEN) Q4 2024 Earnings Call Transcript

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

Mar 17, 2025, 4:05 PM EDT - 7 months ago

FibroGen Reports Fourth Quarter and Full Year 2024 Financial Results

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 3, 2025, 4:45 PM EST - 8 months ago

FibroGen to Report Fourth Quarter and Full Year 2024 Financial Results

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

Feb 20, 2025, 1:08 PM EST - 8 months ago

Amid Mounting Pressure In China, AstraZeneca Buys FibroGen's Chinese Unit For $160 Million

AZN

FibroGen sells China unit to AstraZeneca in deal worth $160 million

Feb 20, 2025, 6:40 AM EST - 8 months ago

FibroGen sells China unit to AstraZeneca in deal worth $160 million

AZN

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

Feb 20, 2025, 6:30 AM EST - 8 months ago

FibroGen Announces the Sale of FibroGen China to AstraZeneca for Approximately $160 Million

FibroGen Appoints David DeLucia as Chief Financial Officer

Dec 16, 2024, 8:05 AM EST - 11 months ago

FibroGen Appoints David DeLucia as Chief Financial Officer

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

Nov 12, 2024, 8:38 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q3 2024 Earnings Conference Call Transcript

FibroGen Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results

FibroGen to Report Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

Aug 9, 2024, 11:32 AM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q2 2024 Earnings Call Transcript

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

Jul 31, 2024, 12:33 PM EDT - 1 year ago

One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program

FibroGen to Report Second Quarter 2024 Financial Results

Jul 30, 2024, 4:07 PM EDT - 1 year ago

FibroGen to Report Second Quarter 2024 Financial Results

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

Jun 6, 2024, 12:38 PM EDT - 1 year ago

FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

Jun 3, 2024, 4:05 PM EDT - 1 year ago

FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen's Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

Jun 3, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces FDA Clearance of Investigational New Drug Application for FG-3165, a Galectin-9 Targeting Monoclonal Antibody, for the Treatment of Patients with Solid Tumors

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

May 23, 2024, 5:05 PM EDT - 1 year ago

FibroGen Announces Presentation of Positive Interim Data from the Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) at the 2024 American Society of Clinical Oncology

FibroGen to Participate in Upcoming Investor Conferences

May 7, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Participate in Upcoming Investor Conferences

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

May 6, 2024, 10:31 PM EDT - 1 year ago

FibroGen, Inc. (FGEN) Q1 2024 Earnings Call Transcript

FibroGen Reports First Quarter 2024 Financial Results

May 6, 2024, 4:02 PM EDT - 1 year ago

FibroGen Reports First Quarter 2024 Financial Results

FibroGen to Report First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Report First Quarter 2024 Financial Results

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

Apr 24, 2024, 4:02 PM EDT - 1 year ago

FibroGen Announces Clinical Data from Dose Escalation Phase 1b Study of FG-3246 (FOR46) in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer will be Presented at the 2024 American Society of Clinical Oncology A

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

Apr 2, 2024, 5:46 PM EDT - 1 year ago

FibroGen Announces Topline Results from Phase 1 Monotherapy Study of FG-3246 in Patients with Metastatic Castration-Resistant Prostate Cancer

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 1 year ago

FibroGen to Present at 23rd Annual Needham Virtual Healthcare Conference

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Mar 11, 2024, 7:00 AM EDT - 1 year ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

Feb 26, 2024, 11:44 PM EST - 1 year ago

FibroGen, Inc. (FGEN) Q4 2023 Earnings Call Transcript

FibroGen regains rights to anemia drug from AstraZeneca

Feb 26, 2024, 4:18 PM EST - 1 year ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

Feb 26, 2024, 4:06 PM EST - 1 year ago

FibroGen Reports Fourth Quarter and Full Year 2023 Financial Results

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

Feb 26, 2024, 4:05 PM EST - 1 year ago

FibroGen Regains All Rights to Roxadustat from AstraZeneca in the United States and Other AstraZeneca Territories, Except China and South Korea

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

Feb 20, 2024, 7:00 AM EST - 1 year ago

FibroGen to Report Fourth Quarter and Full Year 2023 Financial Results

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

Feb 5, 2024, 7:00 AM EST - 1 year ago

FibroGen To Host Part I of Virtual KOL Investor Event Series to Review Pamrevlumab Clinical Program in Pancreatic Cancer on February 13, 2024

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

Jan 25, 2024, 7:00 AM EST - 1 year ago

FibroGen Announces Completion of the Pamrevlumab Arm in Precision Promise, Pancreatic Cancer Action Network's Phase 2/3 Adaptive Platform Trial for Metastatic Pancreatic Cancer

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

Dec 9, 2023, 5:02 PM EST - 2 years ago

FibroGen Presents Data from Phase 3 MATTERHORN Trial of Roxadustat in Patients with Anemia of Lower Risk Transfusion-Dependent Myelodysplastic Syndromes at American Society of Hematology Annual Meeting

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

Nov 6, 2023, 8:30 PM EST - 2 years ago

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

FibroGen Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 4:01 PM EST - 2 years ago

FibroGen Reports Third Quarter 2023 Financial Results

ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 25 at 7:48 AM
$FGEN Procyanidin displayed a synergistic effect with roxadustat on renal anemia in mice https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1678846/abstract
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 25 at 2:05 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $FGEN Current Share Price: $10.88 Contracts: $FGEN January 15, 2027 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
mjtwins16
mjtwins16 Oct. 23 at 6:27 PM
$FGEN https://pubmed.ncbi.nlm.nih.gov/41079599/?utm_source=FeedFetcher&utm_medium=rss&utm_campaign=None&utm_content=0x09UMLZ1ZyMLjbskVJ3kd6MHfZTZyaCGRc7NzobTEJ&fc=None&ff=20251023004005&v=2.18.0.post22+67771e2
0 · Reply
mjtwins16
mjtwins16 Oct. 23 at 6:26 PM
$FGEN
0 · Reply
AceInTheHole18
AceInTheHole18 Oct. 23 at 6:13 PM
$BCTX $FGEN game on!
0 · Reply
MaxMiamiFl
MaxMiamiFl Oct. 23 at 5:05 PM
$FGEN
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 3:04 PM
$FGEN in an hour and a half of trading, the volume of shares is 279 pieces :). Everyone is waiting for something.
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 9:17 AM
$FGEN https://www.kingnet.com.tw/news/single?newId=49293
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 23 at 9:14 AM
$FGEN https://pubmed.ncbi.nlm.nih.gov/41079599/
0 · Reply
Value10
Value10 Oct. 22 at 2:36 AM
$FGEN SEC Earnings Date for FGEN has not been announced, however it is usually the 1st week in November. I would expect some guidance at that time… especially since there now only 2 drugs, no office space, a P.O. Box, little debt… and $150 million in Cash. They may not give it away entirely, but we should get some idea of where we are going.
0 · Reply
NolAsrtormZ
NolAsrtormZ Oct. 21 at 4:19 PM
$GRI only a few tickers know how much iPf data is worth. $PLRX lost 900 million market cap for ipf data $TVRD lost 300 million market cap for ipf data $FGEN went from $16 to $3.00 on ipf data Gri market cap. 5 million
0 · Reply
AceInTheHole18
AceInTheHole18 Oct. 21 at 1:51 PM
$BCTX $FGEN shining stars
0 · Reply
MaxMiamiFl
MaxMiamiFl Oct. 21 at 1:09 PM
$FGEN $14 +..........that's all I want lol
1 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Oct. 21 at 3:26 AM
$FGEN Let’s Gooooooo!
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 21 at 12:09 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $FGEN Current Share Price: $10.38 Contracts: $FGEN January 15, 2027 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 453 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
AceInTheHole18
AceInTheHole18 Oct. 20 at 6:54 PM
$FGEN loading up the truck!
1 · Reply
MaxMiamiFl
MaxMiamiFl Oct. 20 at 12:23 PM
$FGEN
0 · Reply
NolAsrtormZ
NolAsrtormZ Oct. 20 at 11:52 AM
$GRI .... $TVRD failed iPf data lost 300 million market cap $PLRX discontinued ipf data lost 900 million market cap $FGEN failed ipf data went from $16 to $3 Billion $$$ market cap for ipf data =
0 · Reply
MaxMiamiFl
MaxMiamiFl Oct. 19 at 7:45 PM
$FGEN let's have a solid green week 💪
0 · Reply
LiquidThetaLEAPS
LiquidThetaLEAPS Oct. 18 at 3:11 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $FGEN Current Share Price: $10.77 Contracts: $FGEN January 15, 2027 $2 Calls Scale in: $0.21- $0.26 Scale out: $0.33-$0.43 Can Easily Capture: 60% ROI Blended DTE: 455 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 18 at 6:48 AM
$FGEN I’ve shared my thoughts on FibroGen. The text turned out quite lengthy, so I’ve had to post it as an image. Apologies for the English—I used an online translator. I want to emphasize that I’m not trying to impose my views on anyone. This is just my personal hypothesis, based entirely on publicly available information. I have no insider knowledge whatsoever—and of course, I could be wrong...
1 · Reply
ARKADIY_PARAVOZOV
ARKADIY_PARAVOZOV Oct. 17 at 7:22 AM
$FGEN In my opinion, now is the right time to sell the company and for its buyer. The main thing is to agree on an acceptable price for everyone. If I were a director, that's what I would do.
2 · Reply